Download video

7-year update on a Phase II trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL

113 views

VJHemOnc – Video Journal of Hematology & HemOnc

3 years ago

7-year update on a Phase II trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL

7-year update on a Phase II trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL

EHA22: TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +\/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN ...
10:20
EHA22: TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +\/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN ...
by Oncoletter
CLARITY: a Phase 2 trial using venetoclax and ibrutinib
1:00
CLARITY: a Phase 2 trial using venetoclax and ibrutinib
by VJHemOnc – Video Journal of Hematology \& HemOnc
5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL
0:59
5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLL
1:09
MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL
1:36
Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
7-year update on a Phase II trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL
4:44
7-year update on a Phase II trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL
2:43
Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL
1:25
Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL
by OncLive
CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL
1:36
CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
My CLL Treatment - 3rd Full Obinutuzumab Infusion
9:05
My CLL Treatment - 3rd Full Obinutuzumab Infusion
by Todd Dunn
Venetoclax and obinutuzumab combination therapy for CLL
2:03
Venetoclax and obinutuzumab combination therapy for CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
What is 100 – {2[25 – (27 : 9 + 24 – 7)]} : 2 ? Numeric Expression
3:32
What is 100 – {2[25 – (27 : 9 + 24 – 7)]} : 2 ? Numeric Expression
by Estudando Com Questões e Mais
Fixed-duration treatment strategies for frontline and relapsed CLL
0:56
Fixed-duration treatment strategies for frontline and relapsed CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
CLL14 trial: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil
4:30
CLL14 trial: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil
by VJHemOnc – Video Journal of Hematology \& HemOnc
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLL
6:34
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Ibrutinib + Venetoclax for CLL
3:01
Ibrutinib + Venetoclax for CLL
by OncLive
Evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in Richter's transformation
1:52
Evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in Richter's transformation
by VJHemOnc – Video Journal of Hematology \& HemOnc
Emerging ibrutinib-based combinations in CLL
1:56
Emerging ibrutinib-based combinations in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
1:46
Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
by VJHemOnc – Video Journal of Hematology \& HemOnc
ASH CLL highlights: ibrutinib-venetoclax combination \& undetectable MRD in IGHV-mutated patients
1:47
ASH CLL highlights: ibrutinib-venetoclax combination \& undetectable MRD in IGHV-mutated patients
by VJHemOnc – Video Journal of Hematology \& HemOnc
Dr. Smith on the Rationale Behind the Fixed Duration Trial for Ibrutinib\/Venetoclax in CLL
1:31
Dr. Smith on the Rationale Behind the Fixed Duration Trial for Ibrutinib\/Venetoclax in CLL
by OncLive
The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-...
4:39
The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-...
by ecancer
GLOW: Assessing ibrutinib plus venetoclax in CLL
1:54
GLOW: Assessing ibrutinib plus venetoclax in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc